The Price Paradox of Biosimilar-Like Long-Acting Insulin
AJMC,
Findings suggest that Basaglar was not less expensive for patients than Lantus.
The Future of Biosimilar Insulins
Overview of attention for article published in Diabetes Spectrum, August 2016
Altmetric Badge
About this Attention Score
-
In the top 25% of all research outputs scored by Altmetric
-
High Attention Score compared to outputs of the same age (86th percentile)
-
Average Attention Score compared to outputs of the same age and source
Readers on
- mendeley
- 53 Mendeley